Hypertension Research
Online ISSN : 1348-4214
Print ISSN : 0916-9636
ISSN-L : 0916-9636
Experimental studies
A Serine Protease Inhibitor, Nafamostat Mesilate, Suppresses Aldosterone Secretions In Vivo
Hirokuni TETSUOShinji SETOHidefumi YAMAZAKIShoichi NAGAOShin-ichiro OZEKITatsuyuki YAMAGUCHIMasazumi AKAHOSHIKatsusuke YANO
Author information

2004 Volume 27 Issue 12 Pages 979-984


To examine the role of serine proteases in the control of aldosterone (Ald) secretion, we studied the effects of nafamostat mesilate (Naf), a serine protease inhibitor, on in vivo Ald secretion and Ald content in the rat adrenal gland. Either Naf (2 mg/kg/h; n =10) or saline (2 ml/h; n =10) was administered intravenously for 30 min to anesthetized Wistar rats whose left adrenal vein was cannulated selectively via the inferior vena cava. Naf caused a significant decrease in Ald secretion rate compared to saline (1.99±0.32 vs. 3.42±0.56 ng/min, p <0.001), while adrenal blood flow, mean arterial pressure and plasma renin activity in the adrenal venous blood did not differ between the two groups. In a separate trial, adrenal Ald content, adrenal renin content, plasma adrenocorticotropic hormone (ACTH) and plasma potassium did not differ between rats treated with Naf (n =7) and those administered saline (n =7). These data suggested that Naf-inhibitable serine proteases may participate in the control of Ald secretion through mechanism(s) other than hemodynamic changes, adrenal renin, ACTH, and/or plasma potassium. (Hypertens Res 2004; 27: 979-984)

Content from these authors
© 2004 by the Japanese Society of Hypertension
Previous article Next article